| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/AAC.01556-08 |
| P8608 | Fatcat ID | release_ncdwqvl7qffd5e6qz7mpscplse |
| P932 | PMC publication ID | 2681552 |
| P698 | PubMed publication ID | 19237647 |
| P50 | author | Bart J. A. Rijnders | Q77114117 |
| P2093 | author name string | Irma A J M Bakker-Woudenberg | |
| Marian T ten Kate | |||
| Wendy W J van de Sande | |||
| Mehri Tavakol | |||
| Ron A A Mathot | |||
| Wim van Vianen | |||
| P2860 | cites work | Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 |
| Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics | Q33692063 | ||
| Quantitative galactomannan detection is superior to PCR in diagnosing and monitoring invasive pulmonary aspergillosis in an experimental rat model | Q33966364 | ||
| Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model | Q33977551 | ||
| Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity | Q34228214 | ||
| Pharmacokinetics/pharmacodynamics of echinocandins | Q34551922 | ||
| Cytochromes P450 and experimental models of drug metabolism. | Q34778084 | ||
| In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model | Q34881309 | ||
| Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis | Q35007030 | ||
| Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis | Q35134300 | ||
| Pharmacokinetics and pharmacodynamics in the development of antifungal compounds. | Q35543291 | ||
| Clinical utility of antifungal pharmacokinetics and pharmacodynamics. | Q36004448 | ||
| In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. | Q36048229 | ||
| In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. | Q36425025 | ||
| Echinocandin antifungals: review and update | Q36441524 | ||
| In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus | Q36492208 | ||
| Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. | Q36535786 | ||
| Voriconazole : a review of its use in the management of invasive fungal infections | Q36729599 | ||
| Pulmonary aspergillosis: a clinical update | Q36831494 | ||
| Therapeutic outcome in invasive aspergillosis | Q38970340 | ||
| Efficacy of voriconazole in treatment of murine pulmonary blastomycosis | Q39476353 | ||
| Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens | Q39652421 | ||
| Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis | Q39652561 | ||
| Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. | Q42286250 | ||
| In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. | Q42949201 | ||
| Caspofungin prolongs survival of transiently neutropenic rats with advanced-stage invasive pulmonary aspergillosis | Q43111770 | ||
| Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions | Q43183398 | ||
| Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites | Q43641631 | ||
| Pathophysiology of unilateral pulmonary aspergillosis in an experimental rat model | Q44228068 | ||
| Improving the mouse model for studying the efficacy of voriconazole | Q44440584 | ||
| The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human | Q44447139 | ||
| Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin | Q44469440 | ||
| Effect of amphotericin B treatment on kinetics of cytokines and parameters of fungal load in neutropenic rats with invasive pulmonary aspergillosis | Q44548714 | ||
| Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis | Q45063490 | ||
| Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity | Q45066131 | ||
| Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model | Q46148256 | ||
| Safety and pharmacokinetics of coadministered voriconazole and anidulafungin | Q46807629 | ||
| Comparative cost-effectiveness of voriconazole and amphotericin B in treatment of invasive pulmonary aspergillosis | Q46868249 | ||
| Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis | Q46933151 | ||
| Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study | Q46943408 | ||
| Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection | Q48177229 | ||
| Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis | Q61758327 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | aspergillosis | Q259626 |
| pharmacokinetics | Q323936 | ||
| voriconazole | Q412236 | ||
| invasive pulmonary aspergillosis | Q54946623 | ||
| P1104 | number of pages | 9 | |
| P304 | page(s) | 2005-2013 | |
| P577 | publication date | 2009-02-23 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin | |
| P478 | volume | 53 |
| Q92575586 | ASP2397 Is a Novel Natural Compound That Exhibits Rapid and Potent Fungicidal Activity against Aspergillus Species through a Specific Transporter |
| Q47375275 | Activity of Combined Antifungal Agents Against Multidrug-Resistant Candida glabrata Strains |
| Q40120736 | Addition of 17-(allylamino)-17-demethoxygeldanamycin to a suboptimal caspofungin treatment regimen in neutropenic rats with invasive pulmonary aspergillosis delays the time to death but does not enhance the overall therapeutic efficacy |
| Q37263780 | Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions |
| Q33490772 | Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination |
| Q37854724 | Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections? |
| Q37888751 | Anidulafungin: when and how? The clinician's view |
| Q38232492 | Antifungal combination therapy for invasive aspergillosis |
| Q35663841 | Antifungal pharmacokinetics and pharmacodynamics |
| Q51032695 | Aspergillus fumigatus devoid of cell wall β-1,3-glucan is viable, massively sheds galactomannan and is killed by septum formation inhibitors. |
| Q37450705 | Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults |
| Q41172368 | Cardiac response to centrally administered echinocandin antifungals |
| Q28727508 | Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis |
| Q44619968 | Combined therapy of voriconazole and anidulafungin in murine infections by Aspergillus flavus |
| Q53217028 | Current role of echinocandins in the management of invasive aspergillosis. |
| Q34986251 | Discrimination of Aspergillus lentulus from Aspergillus fumigatus by Raman spectroscopy and MALDI-TOF MS. |
| Q40587101 | Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis |
| Q33709967 | Drosophila melanogaster as a model organism for invasive aspergillosis |
| Q35113648 | Efficacy of combination therapy of triazole and echinocandin in treatment of invasive aspergillosis: a systematic review of animal and human studies |
| Q37558822 | Efficacy of the combination of voriconazole and caspofungin in experimental pulmonary aspergillosis by different Aspergillus species |
| Q37263430 | Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates |
| Q41857220 | In vitro activity and in vivo efficacy of anidulafungin in murine infections by Aspergillus flavus |
| Q36171554 | In vitro combination of anidulafungin and voriconazole against intrinsically azole-susceptible and -resistant Aspergillus spp |
| Q36558484 | In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus. |
| Q40273481 | New pharmacological opportunities for the treatment of invasive mould diseases. |
| Q36505281 | Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis. |
| Q37785979 | Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections |
| Q91876531 | Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans |
| Q39269795 | Synergistic effect of anidulafungin combined with posaconazole in experimental aspergillosis |
| Q34775725 | The growing promise of Toll-deficient Drosophila melanogaster as a model for studying Aspergillus pathogenesis and treatment |
| Q37688257 | Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology |
Search more.